SR One Capital Management LP Has $132.13 Million Stock Position in CRISPR Therapeutics AG $CRSP

Key Points

• SR One Capital Management boosted its stake in CRISPR Therapeutics by 94.4% to 2,038,763 shares valued at $132.13 million, making CRSP about 19.1% of SR One’s portfolio and its second-largest holding.
• CRISPR missed quarterly expectations, reporting EPS of ‑$1.37 versus ‑$1.15 expected and revenue of $0.86M versus $4.72M expected, a 97.8% year-over-year revenue decline.
• Insider selling occurred: CEO Samarth Kulkarni and General Counsel James Kasinger sold shares on Feb 19, with total insider sales in the quarter of 99,079 shares worth $5.64M; insiders own 4.30% while institutions hold about 69.2% of the stock.

SR One Capital Management LP increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 94.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,038,763 shares of the company's stock after acquiring an additional 989,812 shares during the quarter. CRISPR Therapeutics comprises approximately 19.1% of SR One Capital Management LP's investment portfolio, making the stock its 2nd biggest holding. SR One Capital Management LP owned about 2.24% of CRISPR Therapeutics worth $132,132,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CRSP. Legal & General Group Plc raised its position in shares of CRISPR Therapeutics by 59.7% during the second quarter. Legal & General Group Plc now owns 129,567 shares of the company's stock worth $6,302,000 after purchasing an additional 48,412 shares during the period. Philadelphia Trust Co. bought a new position in CRISPR Therapeutics in the second quarter valued at approximately $2,444,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $911,000. JPMorgan Chase & Co. increased its position in shares of CRISPR Therapeutics by 98.3% during the third quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company's stock worth $38,459,000 after acquiring an additional 294,222 shares in the last quarter. Finally, Nwam LLC raised its holdings in shares of CRISPR Therapeutics by 455.7% during the third quarter. Nwam LLC now owns 101,769 shares of the company's stock worth $6,770,000 after acquiring an additional 83,454 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total value of $366,324.86. Following the completion of the transaction, the chief executive officer owned 226,106 shares of the company's stock, valued at $11,888,653.48. This trade represents a 2.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 2,112 shares of the company's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $52.58, for a total transaction of $111,048.96. Following the completion of the sale, the general counsel directly owned 85,115 shares in the company, valued at approximately $4,475,346.70. The trade was a 2.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 99,079 shares of company stock valued at $5,643,674. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on CRSP. TD Cowen upped their target price on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a "hold" rating in a research note on Friday, February 13th. Bank of America cut their price target on CRISPR Therapeutics from $90.00 to $89.00 and set a "buy" rating on the stock in a report on Thursday, January 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Chardan Capital lifted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the company a "buy" rating in a research report on Saturday, February 14th. Finally, Needham & Company LLC upped their price target on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday, February 13th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of "Hold" and an average price target of $64.24.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $57.33 on Friday. The stock has a 50 day moving average price of $54.20 and a 200 day moving average price of $57.31. The stock has a market capitalization of $5.50 billion, a PE ratio of -8.79 and a beta of 1.72. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The firm's revenue for the quarter was down 97.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.01) EPS. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.